sectional imaging studies were identified. Renal tumor size was measured as the largest single-dimension diameter on imaging. Growth rates were calculated using linear regression. Kruskal-Wallis test was used to compare growth rates among genetically-defined groups.
INTRODUCTION AND OBJECTIVES: Active surveillance (AS) is recognized as a standard for the management of small renal masses (SRM). Renal cell carcinoma (RCC) can metastasize to the lungs, so yearly chest imaging has been indicated for the follow-up of patients with SRM on AS. However, given the low rates of metastasis from SRM and the potentially increased rates of incidental non-RCC related findings, the necessity of this yearly chest imaging comes into question.
METHODS: We performed a retrospective analysis of 268 patients with SRM enrolled in the AS arm of the Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry at our institution. Chest imaging reports were examined to identify patients with abnormal findings, which were then determined to be actionable or non-actionable based on receipt of further clinical investigations/interventions. RESULTS: Of the 268 patients, 51 (19%) were found to have abnormal baseline chest images; of these 51 images, 22 (43%) were actionable or eventually became actionable, and 29 (57%) were nonactionable. Of the 217 patients with normal baseline images, 23 (11%) developed abnormal findings in subsequent chest imaging. The findings were actionable in 10 (43%) of these 23 patients. Most of the 32 actionable findings were pulmonary nodules >5mm (N[20, 63%) and thyroid nodules (N[8, 25%), for which further chest CT (N[14, 44%), lung biopsies (N[6, 19%), and thyroid ultrasound (N[8, 25%) were performed. None of these patients were found to have metastatic RCC. Most of the 42 non-actionable findings included stable pulmonary nodules <5mm (N[24, 58%) and scarring/postinflammatory changes (N[8, 19%) .
CONCLUSIONS: Routine chest imaging did not reveal metastatic disease in patients with SRM. The potential morbidity and cost of frequent chest imaging in these patients outweigh the chance of detecting metastasis. However, yearly chest imaging "for cause" could still be appropriate in: (1) patients with indeterminate pulmonary findings on baseline imaging, (2) patients with growing SRM, especially those that exceed 0.5cm/year or cross size thresholds of 3cm or 4cm, due to an increased risk of pulmonary metastases, and (3) patients electing crossover to surgical intervention for accurate restaging prior to intervention.
Source of Funding: none

PD07-06 COST BENEFIT ANALYSIS FAVORS SONOGRAPHIC SCREENING FOR RENAL TUMORS
Miki Haifler, Guy Verhovsky*, Yishai Hode Rappaport, Tzriffin, Israel; Michael Leshno, Tel-Aviv Israel; Amnon Zisman, Shmuel Roizman, Tzriffin, Israel INTRODUCTION AND OBJECTIVES: In the last 2 decades, the rate of metastatic Renal Cell Carcinoma (RCC) at diagnosis declined from 33% to 17%. This fact is attributed to massive penetration of imaging tests leading to a marked stage migration. The cost of targeted therapy for metastatic RCC patients is very high. These trends led us to hypothesize that screening for RCC with ultrasound may be cost effective.
OBJECTIVE: To assess the cost effectiveness of screening with ultrasound (US) for renal tumors in the general population over 60 years of age.
METHODS: Using the Markov model, a mathematical framework was set up describing the course of disease with and without screening for RCC. Quality Adjusted Life Year (QALY) and financial costs were the outputs of the model. RESULTS: Average costs for the screening strategy was 137.4 U$ and for non-screening was 31.4 USD. Screening and non-screening strategy would add an average of 21.7396 and 21.7385 QALY, respectively. An increase of 0.001 QALY equates to Incremental Cost Effectiveness Ratio (ICER) of 86.4 USD, the cost which is considered cost effective for 1 QALY point is approximately 27,548.21 U$. The two variables most influential on the model output were prevalence of RCC and US cost.
CONCLUSIONS: To our knowledge, this is the sole cost benefit screening study performed for RCC in the targeted therapy era. Screening for renal tumors using abdominal ultrasonography at a cost of 35.81 USD per exam is cost effective.
